50O - A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Proffered Paper Session 1
Topics Immunotherapy
Presenter Ruth Plummer
Citation Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048
Authors R. Plummer1, S. Halford2, P. Jones2, S. Wedge3, S. Hirschberg2, G. Veal1, G. Payne4, M. Chenard-Poirier4, H. Keun5, U. Banerji6
  • 1Newcastle University, NE2 4HH - Newcastleupon Tyne/GB
  • 2Cancer Research UK Angel Building, London/GB
  • 3Newcastle University, Newcastle upon Tyne/GB
  • 4Institute of Cancer Research ICR, London/GB
  • 5Imperial College London - Hammersmith Hospital, London/GB
  • 6Drug Development Unit  , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB


A key metabolic alteration in tumour cells is increased dependency on glycolysis, resulting in the production of lactate which is transported out of cells by MCTs. Inhibition of MCT-1 can constrain cancer cell growth in preclinical models. We report results on the phase I study of AZD3965, a FIC inhibitor of MCT-1.